SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- David Koos, Chairman and CEO of San Diego-based Bio-Matrix Scientific Group, Inc. (OTC Bulletin Board: BMSN) announced today that the important discovery reported on Wednesday, March 25 by researchers at the National Institutes of Health (NIH; www.nih.gov), which has implications for Leukemia treatment and artificially culturing blood cells, validates a new direction for stem cell "storage" facilities that meet rigid state and federal regulatory requirements. The researchers deciphered a key sequence of events governing whether the stem cells that produce red and white blood cells remain anchored to the bone marrow, or migrate into the circulatory system - an important discovery that will advance understanding of how blood cells and immune cells are generated.
"The findings of NIH researchers have implications for culturing infection-fighting immune cells outside the body, where they could be temporarily held in storage during chemotherapy and other treatments which suppress the immune system. This discovery confirms a new trend for commercial stem cell storage facilities for research and treatment of diseases, and their important role in public and private stem cell research efforts now and into the future," said Koos.
BMSN, an emerging research and development biotechnology company, opened its commercial cryogenic stem cell storage and processing facility in 2008 focusing on stem cells derived from cord blood and peripheral blood. BMSN's 15,000 sq. ft. cryogenic stem cell banking facility is highly secured and technologically advanced and is now fully operational.
"There are about 30 private cord blood storage facilities in the U.S. and more than 150 of these facilities located worldwide," stated Koos.
About Bio-Matrix Scientific Group
Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotech research and development company headquartered in San Diego, Ca. with a 15,000 square foot facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. The company also commercializes medical devices and monitoring systems for the growing worldwide stem cell research market.
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
|SOURCE Bio-Matrix Scientific Group Inc.|
Copyright©2009 PR Newswire.
All rights reserved